• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Remoxipride     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:Tranquilizer104470232, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAntipsychoticsyago:WikicatAtypicalAntipsychoticsyago:WikicatMolecularFormulasyago:WikicatWithdrawnDrugsyago:Abstraction100002137yago:Agent114778436yago:CausalAgent100007347yago:Communication100033020yago:Drug103247620yago:DrugOfAbuse103248958yago:Formula106816935yago:MajorTranquilizer103713736yago:Matter100020827yago:Medicine103740161yago:Message106598915yago:MolecularFormula106817173yago:PhysicalEntity100001930yago:PsychotropicAgent104017429drugyago:Sedative-hypnotic104166841yago:Sedative104166553yago:Statement106722453yago:Substance100020090yago:Tranquilizer104470232 New Facet based on Instances of this Class

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.